# Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome

Study · id `cardio:ct-nct04023565` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04023565](<https://clinicaltrials.gov/study/NCT04023565>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04023565

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04023565. Allocation not applicable; no masking; primary purpose treatment. Start 2019-03-11 (actual); primary completion 2020-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04023565, source copy `cardio:ctgov-nct04023565-2019-07-23`, retrieved 2026-10-26)
- Started: 2019-03-11 (actual) (ClinicalTrials.gov record NCT04023565, source copy `cardio:ctgov-nct04023565-2019-07-23`, retrieved 2026-10-26)
- Primary completion: 2020-06-30 (anticipated) (ClinicalTrials.gov record NCT04023565, source copy `cardio:ctgov-nct04023565-2019-07-23`, retrieved 2026-10-26)
- Completion: 2020-12-30 (anticipated) (ClinicalTrials.gov record NCT04023565, source copy `cardio:ctgov-nct04023565-2019-07-23`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT04023565, source copy `cardio:ctgov-nct04023565-2019-07-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04023565-2019-07-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome
- Acronym: COMPOSER
- Condition: Arterial Hypertension
- Condition: Metabolic Syndrome
- Intervention (Drug): perindopril + moxonidine
- Lead sponsor: Sergey V. Nedogoda
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 48fc84434e68a8fa266ebe5e8323bb28f6df849d1f33516f4592914b2ce36bab
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
